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restate their intriguing hypothesis regarding the role of time-dependent sensitization (TDS) in the mechanism of action of antidepressant drugs and electroconvulsive therapy (ECT). Considerable evidence from animal studies is presented in support of the hypothesis. Antelman et al 1 suggest that the therapeutic effect of these treatments in major depression is due to the biological process of TDS that is initiated by the first administration of the treatment and develops thereafter with the passage of time. Since the ultimate neurobiological and therapeutic effect is a consequence of the initial treatment, the implication for clinical practice is that administration of additional doses of the drug or additional sessions of ECT during the intervening period is unnecessary.
ECT is a highly effective treatment for severe depression and is widely used in the management of patients who have not responded to antidepressant drugs. The basis of the treatment is an electrically induced, generalized seizure (modified by prior administration of an anesthetic drug and a muscle relaxant) that is administered twice or three times weekly up to a total of 6-12 sessions. In support of their hypothesis, Antelman et al 1 cite the study of Jagdeesh et al 2 who showed that a single bilateral ECT followed by five sham sessions (anesthesia and muscle relaxant only) on alternate days was as effective in alleviating depression as six real treatments administered according to the same schedule. ECT is an important test of the Antelman et al 1 hypothesis because it is not confounded by pharmacokinetic effects, as are antidepressant drug regimens.
The results of two random assignment, double blind, controlled studies 3,4 conducted by our group cast a different light on this issue. The purpose of both studies was to compare the antidepressant efficacy and cognitive effects of bilateral, brief pulse ECT administered twice (ECT × 2) or three times weekly (ECT × 3). Double blind conditions were achieved by the administration of one sham ECT (anesthesia and muscle relaxant only) per week to the ECT × 2 group. In Study 1, patients administered ECT × 2 could receive up to eight real ECTs and ECT × 3 up to 12. 3 In Study 2, the number of real ECTs was limited to eight in both groups. 4 In both studies there was no significant difference in antidepressant outcome between the ECT × 2 and ECT × 3 regimens. Both groups improved significantly and to a similar degree at the end of the treatment course.
In this regard, our findings are in accordance with those of Jageesh et al. 2 In both our studies, however, there was a significant difference in rate of response between the ECT × 2 and ECT × 3 groups. Patients who received three real ECT sessions per week improved significantly faster and had lower Hamilton Depression Scale scores at interim assessments than patients who received only two real treatments per week. The time course of the effect of ECT differed significantly between the two schedules and clearly favored the more frequent schedule (ECT × 3). In these 3, 4 and subsequent 5 analyses we clearly showed that the more rapid response of the ECT × 3 group was due to the greater frequency of real ECT administration.
If the antidepressant effect of an ECT series is due to the first treatment only, the effects of this treatment evolving with time, additional treatments administered in the interim should not alter the rate of response. In two studies we showed that the therapeutic effect of ECT could be modified according to the frequency of administration of the treatment. Thus, whatever biological process underlies the antidepressant effect of ECT cannot be solely dependent on effects induced by the first ECT and there must be a biologically significant contribution of the interim treatments. Support for this view comes from a study by Kellner et al 6 in which once and three times weekly ECT schedules were compared in elderly patients with major depression. The three times weekly schedule was clearly more effective.
These findings pose an important question to the Antelman et al 1 hypothesis, as applied to clinical ECT.
